echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Upstart BTK inhibitor sells at least $11 billion globally in 2021

    Upstart BTK inhibitor sells at least $11 billion globally in 2021

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    TextCai Cai

    In today's new drug rivers and lakes, BTK inhibitor drugs, as a member of chemical drugs, have made a dawn in the battlefield where biological drugs shine

    Under the influence of many factors such as large indications, large market potential, and the market is not crowded, BTK inhibitors have naturally become the favorite of major pharmaceutical giants

    At present, there are 5 BTK inhibitors approved for marketing globally

    Ibrutinib is the first approved BTK inhibitor and has been approved for the treatment of various blood diseases, autoimmune-related diseases such as stem cell transplantation, immune resistance after transplantation, and arthritis

    Globally Approved BTK Inhibitors

    (Source: CITIC Securities Research)

    Sales of major BTK inhibitors have continued to grow since their launch

    Ibrutinib sales rose from $1.

    In 2020, the total global sales of BTK inhibitors has exceeded 10 billion US dollars.

    According to Frost & Sullivan's sub-report, in the future, with the increase in the number of patients and the approval of new indications, the global BTK inhibitor market will grow rapidly, and the market size is expected to grow at a CAGR of 22.

    (Data source: annual reports of each company, tirabrutinib sales in 2021 are the data from listing to March 2021)

    At present, many domestic pharmaceutical companies are also deploying BTK inhibitors

    At present, the three BTK inhibitors that have been marketed in China only cover the two hematological indications of CLL/SLL and MCL

    Domestic BTK inhibitors in Phase II or above clinical trials

    (Source: CITIC Securities Research)

    Reference: Biotech rookies, high-growth tumor and autoimmune innovative drug companies

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.